Accessibility Menu
Viva Biotech logo

Viva Biotech(SEHK) 1873

Market CapHK$2.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-70%
5 Year-81%
1 Year-50%
1 Month+5%
HK$1.33
+0.00%
+0.00Today
Viva Biotech last closing stock price
MetricPriceDate
Last closeHKD 1.342026-09-02
Viva Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-14.42%HKD 1.562026-08-26
1 month+5.12%HKD 1.272026-08-03
3 month+6.8%HKD 1.252026-06-04
Year to date-25.83%HKD 1.802025-12-31
1 year-49.62%HKD 2.652025-09-02
3 year-8.56%HKD 1.462023-08-31
5 year-80.54%HKD 6.862021-09-03
Since inception-69.72%HKD 4.392019-05-09

Viva Biotech Financials at a Glance

Market Cap

HK$2.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥3.73B

Net Income (TTM)

CN¥349.22M

EPS (TTM)

HK$0.09

P/E Ratio

14.12

Dividend

HK$0.00

Beta (Volatility)

0.02 (Low)

Price

HK$1.33

Volume

858,000

Open

HK$1.34

Previous Close

HK$1.33

Daily Range

HK$1.31 - HK$1.36

52-Week Range

HK$1.04 - HK$3.27

Estimated Earnings Date

Apr 1, 2027

1873 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Viva Biotech

Viva Biotech Holdings is a biotechnology company based in Shanghai, China, specializing in structure-based drug discovery services for global pharmaceutical and biotechnology clients. Founded in 2008, the company offers a comprehensive suite of services, including discovery biology, chemistry, and antibody drug research.

Products and Services
  • Comprehensive drug discovery services including protein expression and purification
  • Contract development and manufacturing services for small molecule APIs
  • Specialized antibody drug research and development services
Growth Outlook
  • Revenue increased to CNY 897.57 million in Q4 2025, up from CNY 831.87 million in Q2 2025
  • Gross profit margin improved to 35.2% in Q4 2025, indicating operational efficiency
  • Strong demand for drug discovery services supports future revenue growth
Financial Highlights
  • Net income of CNY 97.96 million reported in Q4 2025, showcasing profitability
  • Operating income margin of 8.6% in Q4 2025 reflects effective cost management
  • Current ratio of 1.5 indicates strong liquidity position
Viva Biotech Holdings operates in a rapidly evolving biotechnology sector, providing essential services that cater to the increasing demand for drug development. The company's focus on structure-based drug discovery and its extensive service offerings position it well for future growth. Recent financial performance highlights a positive trend, with increasing revenues and improving profit margins, suggesting a robust operational framework. The liquidity position further enhances the company's ability to navigate market challenges and capitalize on emerging opportunities.
AI Generated • Aug 12, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

2,169

CEO

Chen Mao

Website

www.vivabiotech.com

Headquarters

Shanghai, SH 201318, CN

1873 Financials

Key Financial Metrics (TTM)

Gross Margin

34.55%

Operating Margin

10.05%

Net Income Margin

9.36%

Return on Equity

4.45%

Return on Capital

3.63%

Return on Assets

2.57%

Earnings Yield

7.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$2.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.07B

Volume

858.00K

Avg. Volume

5.66M

Financials (TTM)

Gross Profit

CN¥1.34B

Operating Income

CN¥413.93M

EBITDA

CN¥809.51M

Operating Cash Flow

CN¥778.84M

Capital Expenditure

-CN¥279.90M

Free Cash Flow

CN¥498.94M

Cash & ST Invst.

CN¥1.06B

Total Debt

CN¥897.96M

Viva Biotech Performance Analysis

Viva Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 2,767,221,0099.1%
20232023-12-31CNY 2,381,909,373-13.9%
20242024-12-31CNY 2,153,974,381-9.6%
20252025-12-31CNY 1,875,624,605-12.9%
Viva Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-312.3%
Q22025-06-30-17.2%
Q42025-12-317.9%
Q22026-06-3010.6%
Viva Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.32N/A
20232023-12-31CNY -0.16-50.7%
20242024-12-31CNY 0.06N/A
20252025-12-31CNY 0.1061.2%
Viva Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-66.8%
Q22025-06-30176.2%
Q42025-12-31-10.8%
Q22026-06-30-24.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥992.63M

+1.1%

Gross Profit

CN¥337.01M

-0.6%

Gross Margin

33.95%

N/A

Market Cap

HK$2.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$1.27M

N/A

Employees

2,169

N/A

Net Income

CN¥78.97M

-32.4%

EBITDA

CN¥211.59M

-1.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥1.06B

+2.0%

Total Debt

CN¥897.96M

-41.7%

Accounts Receivable

CN¥254.99M

-42.9%

Inventory

CN¥398.62M

+76.8%

Long Term Debt

CN¥299.51M

-66.3%

Short Term Debt

CN¥598.45M

-8.4%

Return on Assets

2.57%

N/A

Return on Invested Capital

3.33%

N/A

Free Cash Flow

CN¥239.63M

+899.4%

Operating Cash Flow

CN¥335.15M

+120.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,634.27-0.01%
^DJIDJI
$52,797.46-0.01%
^IXICNASDAQ
$26,099.39-0.01%
BTCBitcoin
$77,103.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About 1873

What is the current price of Viva Biotech?

Viva Biotech is trading at HK$1.33 per share.

What is the 52-week range for Viva Biotech?

Over the past 52 weeks, Viva Biotech has traded between HK$1.04 and HK$3.27.

How much debt does Viva Biotech have?

As of the most recent reporting period, Viva Biotech reported total debt of CN¥1.48B.

How much cash does Viva Biotech have on hand?

Viva Biotech reported CN¥1.21B in cash and cash equivalents in its most recent financial results.

What is Viva Biotech’s dividend yield?

Viva Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services